Biomm S.A. (BVMF:BIOM3)

Market Cap	729.42M -37.7%
Revenue (ttm)	384.42M +176.5%
Net Income	30.33M
EPS	0.22
Shares Out	136.85M
PE Ratio	24.07
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,300
Open	5.61
Previous Close	5.52
Day's Range	5.31 - 5.61
52-Week Range	4.82 - 9.75
Beta	0.49
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Biomm

Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tu...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 130
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: BIOM3

Financial Performance

In 2025, Biomm's revenue was 269.30 million, an increase of 88.45% compared to the previous year's 142.91 million. Losses were -6.69 million, -91.34% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error